Major bleeding after hospitalization for deep-venous thrombosis
- PMID: 10569295
- DOI: 10.1016/s0002-9343(99)00267-3
Major bleeding after hospitalization for deep-venous thrombosis
Abstract
Purpose: Most studies of oral anticoagulant-related bleeding have analyzed the incidence of adverse outcomes among patients with a variety of different conditions and without any comparison with a control group. We determined the incidence, time course, and risk factors associated with major bleeding after hospital discharge among patients with deep-vein thrombosis, and estimated the excess risk of bleeding associated with oral anticoagulant therapy.
Methods: A total of 22,000 adults were hospitalized in California for 3 or more days with a diagnosis of deep-venous thrombosis between January 1, 1992, and September 30, 1994. We determined the risk factors associated with readmission for bleeding. We compared the incidence of readmission for bleeding with comparison cohorts of patients with pneumonia or cellulitis who were matched for age, gender, race, and length of hospital stay.
Results: Of 21,250 patients with deep-venous thrombosis who were discharged without bleeding, 1.4% were readmitted for bleeding within 91 days; the rate was 2.7 times greater in the first 30 days than in the next 61 days. Risk factors for bleeding included hospitalization with gastrointestinal bleeding during the previous 18 months (relative hazard [RH] = 2.6, 95% confidence interval [CI]: 1.6 to 4.1), hospitalization with an alcohol-related diagnosis during the previous 18 months (RH = 2.6, 95% CI: 1.4 to 4.8), chronic renal disease (RH = 2.4, 95% CI: 1.4 to 4.2), female gender (RH = 1.7, 95% CI: 1.3 to 2.2), presence of a malignancy (RH = 1.6, 95% CI: 1.2 to 2.2), nonwhite race (RH = 1.6, 95% CI: 1.2 to 2.1), and age over 65 years (RH = 1.3, 95% CI: 1.0 to 1.7). Significantly more women (n = 40) had intracranial bleeding than men (n = 18, P = 0.02). In the comparison cohorts, the incidence of readmission for bleeding within 3 months of discharge was 0.7%, and the relative risk (RR) of readmission was greater in those with deep-venous thrombosis than in those with cellulitis (RR = 2.0, 95% CI: 1.6 to 2.5) or pneumonia (RR = 2.0, 95% CI: 1.7 to 2.5).
Conclusions: The incidence of rehospitalization for bleeding was greatest in the first 30 days after discharge, and was approximately twice that seen in patients hospitalized for cellulitis or pneumonia. Further studies are needed to determine why women and nonwhite patients are at increased risk for anticoagulant-related bleeding.
Comment in
-
Bleeding after initiation of anticoagulant therapy for deep vein thrombosis.Am J Med. 1999 Nov;107(5):517-8. doi: 10.1016/s0002-9343(99)00272-7. Am J Med. 1999. PMID: 10569309 No abstract available.
Similar articles
-
Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.Thromb Haemost. 2017 Oct 5;117(10):1841-1847. doi: 10.1160/TH17-03-0210. Epub 2017 Jun 22. Thromb Haemost. 2017. PMID: 28640322
-
The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism.Arch Intern Med. 2003 Apr 28;163(8):917-20. doi: 10.1001/archinte.163.8.917. Arch Intern Med. 2003. PMID: 12719200
-
Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions.J Am Heart Assoc. 2016 Oct 6;5(10):e003788. doi: 10.1161/JAHA.116.003788. J Am Heart Assoc. 2016. PMID: 27792638 Free PMC article.
-
Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.Prescrire Int. 2013 May;22(138):129-33. Prescrire Int. 2013. PMID: 23819181 Review.
-
Prophylaxis against venous thromboembolism in hospitalized medical patients: an evidence-based and practical approach.Pol Arch Med Wewn. 2008 Apr;118(4):209-15. Pol Arch Med Wewn. 2008. PMID: 18575420 Review.
Cited by
-
Duration of anticoagulation for venous thromboembolism.J Thromb Thrombolysis. 2001 Sep;12(1):59-65. doi: 10.1023/a:1012790511790. J Thromb Thrombolysis. 2001. PMID: 11711690 Review.
-
A role for pharmacists in community-based post-discharge warfarin management: protocol for the 'the role of community pharmacy in post hospital management of patients initiated on warfarin' study.BMC Health Serv Res. 2011 Jan 25;11:16. doi: 10.1186/1472-6963-11-16. BMC Health Serv Res. 2011. PMID: 21261998 Free PMC article.
-
Impact of warfarin discharge education program on hospital readmission and treatment costs.Int J Clin Pharm. 2018 Jun;40(3):721-729. doi: 10.1007/s11096-018-0631-y. Epub 2018 Mar 31. Int J Clin Pharm. 2018. PMID: 29605947
-
Assessing the risk of recurrent venous thromboembolism--a practical approach.Vasc Health Risk Manag. 2015 Aug 17;11:451-9. doi: 10.2147/VHRM.S83718. eCollection 2015. Vasc Health Risk Manag. 2015. PMID: 26316770 Free PMC article. Review.
-
Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study.Front Pharmacol. 2017 Jun 7;8:347. doi: 10.3389/fphar.2017.00347. eCollection 2017. Front Pharmacol. 2017. PMID: 28638342 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical